Lin, D. I., Quintanilha, J. C. F., Danziger, N., Lang, L., Levitan, D., Hayne, C., . . . Wehn, A. K. (2024). Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab. npj Precision Oncology, 8(1), 1-9. https://doi.org/10.1038/s41698-024-00679-7

Lin, Douglas I., et al. "Pan-tumor Validation of a NGS Fraction-based MSI Analysis as a Predictor of Response to Pembrolizumab." Npj Precision Oncology 8, no. 1 (2024): 1-9. https://doi.org/10.1038/s41698-024-00679-7.

Lin, Douglas I., et al. "Pan-tumor Validation of a NGS Fraction-based MSI Analysis as a Predictor of Response to Pembrolizumab." Npj Precision Oncology, vol. 8, no. 1, 2024, pp. 1-9, https://doi.org/10.1038/s41698-024-00679-7.